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Abstract
The objectives of this study were to investigate the immune response to intradermal immunization with wall teichoic acid
(WTA) and the effect of MBL deficiency in a murine model of infection with methicillin-resistant Staphylococcus aureus
(MRSA). WTA is a bacterial cell wall component that is implicated in invasive infection. We tested susceptibility to MRSA
infection in wild type (WT) and MBL deficient mice using two strains of MRSA: MW2, a community-associated MRSA (CA-
MRSA); and COL, a healthcare-associated MRSA (HA-MRSA). We also performed in vitro assays to investigate the effects of
anti-WTA IgG containing murine serum on complement activation and bacterial growth in whole blood. We found that MBL
knockout (KO) mice are relatively resistant to a specific MRSA strain, MW2 CA-MRSA, compared to WT mice, while both
strains of mice had similar susceptibility to a different strain, COL HA-MRSA. Intradermal immunization with WTA elicited
and augmented an anti-WTA IgG response in both WT and MBL KO mice. WTA immunization significantly reduced
susceptibility to both MW2 CA-MRSA and COL HA-MRSA, independent of the presence of MBL. The protective mechanisms
of anti-WTA IgG are mediated at least in part by complement activation and clearance of bacteria from blood. The
significance of these findings is that 1) Intradermal immunization with WTA induces production of anti-WTA IgG; and 2) This
anti-WTA IgG response protects from infection with both MW2 CA-MRSA and COL HA-MRSA even in the absence of MBL,
the deficiency of which is common in humans.
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Introduction
Staphylococcus aureus, a Gram-positive bacterium, is a common
commensal organism on skin and mucosa that can also cause
serious infections in the skin and other soft tissues, bones and blood
[1]. The morbidity and mortality of S. aureus infection have greatly
increased with the rapid emergence of a much more virulent and
antibiotic resistant strain that is identified by its resistance to the
antibiotic methicillin, and which is therefore known as methicillin-
resistant S. aureus (MRSA) [1,2,3]. All strains of S. aureus, including
MRSA, are covered by a thick cell wall containing peptidoglycan,
lipoteichoic acid (LTA) and wall teichoic acid (WTA) [4,5]. WTA
of S. aureus is a glycopolymer that covalently links to peptidoglycan.
It is composed of an N-acetylmannosamine (ManNAc)-(b-1,3)-N-
acetylglucosamine (GlcNAc) disaccharide with two glycerol
phosphates, followed by 10 to 40 ribitol phosphate repeating
units [4,6]. WTA has been identified as an adhesion molecule that
binds to host cells and promotes bacterial colonization and tissue
invasion [7,8,9,10].
The host defense system has two principal divisions, innate
immunity and adaptive immunity, which are tightly coordinated
in their functions. The innate immune system consists of innate
immune cells, such as epithelial cells and phagocytes, and soluble
factors such as complement proteins, coagulation factors and
pattern recognition molecules, including mannose-binding lectin
(MBL) [11]. Although genetic deficiency of MBL in mice increases
infection susceptibility to certain pathogens, including S. aureus, this
association is less apparent in humans, particularly in adults
[12,13,14,15].
Differences in antigen presentation, including the route of
exposure, the context of antigen preparation, and adjuvant factors,
are important determinants of host immune responses. It has been
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found in prior investigations that immunization of various vaccines
by an intradermal route can elicit an effective immune response
that protects from infection, whereas subcutaneous immunization
does not elicit a protective immune response [16,17,18,19].
Another relevant finding from our previous work is that
commercially available WTA can be contaminated with other
pathogen components, including LTA and peptidoglycan, which
are known to modulate other pathways [20,21].
We have recently discovered that healthy humans (that is, with
no known pathogenic infection) have WTA-specific IgG in their
blood, and that in purified form this anti-WTA IgG enhances the
opsonophagocytic killing of S. aureus [21,22]. Moreover, anti-WTA
IgG competes with MBL for S. aureus binding, and it activates the
classical complement pathway [21]. Anti-WTA IgG may also be
protective since WTA has been found to induce abscess formation
when it is subcutaneously injected with a foreign body [10,23].
Consequently, these findings support the hypothesis that stimu-
lating and enhancing an anti-WTA IgG response would help to
eliminate bacteria and to reduce abscess formation.
In this study, we investigated whether intradermal WTA
immunization would induce the anti-WTA IgG response, and
whether this response was protective from infection with two
strains of MRSA, COL HA-MRSA and MW2 CA-MRSA. In
addition, considering the interaction between WTA and MBL,
and given the high prevalence of MBL deficiency in humans, we
examined whether the presence of MBL altered the anti-WTA
IgG response and the efficacy of anti-WTA immunity in MRSA
infection, using both in vivo and in vitro systems.
Materials and Methods
Purification of S. aureus WTA
WTA was prepared using previously reported methods [21,22].
Briefly, WTA was purified from S. aureus strain T384, which is
deficient in both a peptidoglycan O-acetyltransferase (oatA) gene
and a lipoprotein diacylglycerol transferase (lgt) gene from S. aureus
strain RN4220 [24]. The lgt mutation results in the absence of
bacterial lipoproteins [20], and so WTA purified from the S. aureus
strain T384 is not contaminated with bacterial lipoproteins. The
oatA mutation makes S. aureus peptidoglycan sensitive to lysozyme.
WTA attached to insoluble peptidoglycan was cleaved by
treatments with lysostaphin and lysozyme. The solubilized WTA
linked to a monomeric unit of peptidoglycan was purified with
HiTrap-Q column chromatography. Complete digestion of
polymeric peptidoglycan was confirmed by loss of melanization
activity in insect hemolymph [25], demonstrating that the purified
WTA did not contain polymeric peptidoglycan. Purified WTA was
dissolved in PBS and aliquots were stored at 280u C.
WTA immunization
MBL KO mice were generated and backcrossed on to a C57B/
6J genetic background as described previously [12,26]. All mice
used in this study were 6–8 weeks old and were maintained in a
specific pathogen free (SPF) environment. All animal experiments
were performed under a protocol approved by the Subcommittee
on Research Animal Care at the Massachusetts General Hospital.
Immunization experiments were performed using previously
described methods with minor modifications [27]. Briefly, the
purified WTA (5 mg in 50 ml PBS) was injected intradermally into
the ventral skin using a 30 G needle (BD Biosciences) attached to a
1 ml syringe (BD Biosciences). The dose was calculated based on
results from our previous studies [27,28]. A control group was
injected with 50 ml PBS in a similar manner. WTA or PBS control
was injected on days 0, 20, 40, and 60. 10 days after each
immunization, serum was collected by making a shallow cut in the
tail vein and stored at 280u C. Day 0 serum collections were
performed on day -5. Anti-WTA IgG titers were determined using
a previously described ELISA method with minor modifications
[27]. Briefly, a 384 well plate was coated with 2 mg of purified
WTA and incubated with serially diluted mouse serum. Bound
mouse IgG was detected using alkaline phosphatase-conjugated
anti-mouse IgG (Promega) with p-nitrophenylphosphate substrate
(pNPP, Sigma-Aldrich). A standard curve was generated from
using murine IgG of known concentration. The chromogenic
reaction was assayed by measuring absorbance (OD) at 405 nm
(Molecular Devices).
Infection studies in vivo
We chose a murine model of abscess formation following
systemic bacterial infection because S. aureus is known to cause
abscesses in a process mediated at least in part by WTA [10,23]. In
the model, abscesses (Figure S1) developed following systemic
inoculation of sub-lethal inoculums of bacteria (bacteremia). Two
S. aureus strains, COL HA-MRSA and MW2 CA-MRSA, were
obtained from Dr. David C. Hopper of the Infection Control Unit
at Massachusetts General Hospital and prepared as previously
described [12]. Briefly, bacteria were grown in Columbia broth
supplemented with 2% NaCl and harvested in the mid log phase.
Washed bacteria were resuspended at 56106 colony forming units
(cfu)/ml in saline and 0.2 ml of the suspension was intravenously
injected. On day 10, mice were euthanized and the lung, liver,
spleen, heart, and kidneys were examined for abscess formation.
Optimal inoculation dosing and the time course for abscess
formation were determined in our preliminary studies. Two
kidneys from each mouse were combined and homogenized with
1 ml of PBS. Serially diluted homogenates were cultured in
duplicate on tryptic soy agar (TSA) plates and resulting S. aureus
colonies were counted.
Complement activation assays
Complement activation was assayed by C4c deposition activity
using previously described methods with minor modifications
[12,29]. C4c is cleaved from C4 upon activation of the classical
pathway. Briefly, a 384 well assay plate was coated with purified
WTA (1 mg/well) and blocked. Mouse serum diluted 1:100,000 in
tris buffered saline was added to each well and incubated in 20 ml
total volume. After washing, 20 ng human C4 was added to each
well and incubated at 37uC for 90 min. After washing, wells were
sequentially incubated with rabbit anti-human C4c antibody and
biotinylated anti-rabbit antibody followed by alkaline phosphatase
conjugated anti-rabbit antibody (ABP-AP, Vector laboratories).
Samples were developed using p-NPP substrate and absorbance
was measured at 405 nm. Assays were performed in triplicate
using 4 samples each from PBS control or WTA immunized MBL
KO mice. WT mice were not included as the purpose of these
experiments was to examine the complement activation activity of
anti-WTA IgG, which competes with MBL for binding and
complement activation [21].
Ex vivo whole blood assays
Whole blood assays were performed using previously described
methods with minor modifications [12]. Bacteria, MW2 CA-
MRSA and COL HA-MRSA strains, were cultured and used as
described above. Naı¨ve MBL KO and WT mice were euthanized
and blood was collected by cardiac puncture with hirudin (Sigma-
Aldrich) as an anticoagulant. 25 ml of whole blood was mixed with
20 ml of mouse serum obtained from MBL KO mice immunized
with WTA or PBS control. Four serum samples from each WTA
Wall Teichoic Acid Elicits Bactericidal Response
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or PBS control immunized mouse were used. These mixtures were
added to 5 ml of bacterial suspension containing 2500 cfu and
incubated for 2 hrs at 37u C. Samples were serially diluted in
EDTA-saline solution and then cultured on TSA plates for colony
counting as described above. Assays were performed in duplicate
and repeated twice.
Statistical analysis
All data were analyzed using JMP software (SAS Institute, Inc).
The methods of statistical analysis were indicated in each figure. p
values less than 0.05 were considered to be significant.
Results
MBL deficiency is relatively protective against MW2 CA-
MRSA infection although there is little effect on COL HA-
MRSA infection in mice
We have previously reported that MBL KO mice are
susceptible to infection with certain pathogens, including antibiotic
sensitive strains of S. aureus [12]. In order to determine the effect of
MBL on susceptibility to infection with MW2 CA-MRSA and
COL HA-MRSA, MBL KO and WT mice were evaluated using
the abscess formation model as described in the Materials and
Methods (Figure S1). Of the organs examined – kidney, liver, lung,
heart, and spleen – abscesses were predominantly observed in the
kidney with both MW2 CA-MRSA and COL HA-MRSA
infection. The incidence of kidney abscess was similar in both
MBL KO and WT mice in COL HA-MRSA infection (Table 1).
In contrast, following MW2 CA-MRSA infection, no abscess
formation was observed in MBL KO mice although 42% of WT
mice had kidney abscess (Table 1). These results demonstrate that
the kidney is susceptible to abscess formation, and that MBL has a
variable role depending on the S. aureus strain, in that MBL
deficiency has little effect on COL HA-MRSA infection whereas it
contributes to decreased MW2 CA-MRSA infection [10].
Intradermal immunization with WTA elicits and
augments anti-WTA IgG responses in both MBL sufficient
and MBL deficient mice
We have previously found that healthy people have detectable
titers of WTA specific IgG in serum [21]. Moreover, we have also
demonstrated that purified anti-WTA IgG competes with MBL for
recognition and phagocytosis of S. aureus [21]. It has been reported
that subcutaneous injection of a mixture of WTA and an irritant
induces abscess formation in murine skin, suggesting that WTA
plays a role in abscess formation [10]. Based on these observations,
we hypothesized that WTA immunization would induce an anti-
WTA IgG response, resulting in reduced susceptibility to MRSA
infection and abscess, regardless of MBL deficiency in mice.
Therefore, we next examined anti-WTA IgG response following
intradermal WTA immunization in both MBL KO and WT mice.
The intradermal injection route was chosen based on recent
reports of induction of protective immunity against several
pathogens using this route of immunization [16,17,18,19].
Prior to immunization (day 0), naı¨ve WT and MBL KO mice
had undetectable or very little anti-WTA IgG titers (Figures 1A
and 1B, respectively). In WT mice, anti-WTA IgG titers
significantly increased after the second WTA immunization and
continued to increase until after the fourth immunization
(Figure 1A). An anti-WTA IgG response was not observed
following injection of PBS control (Figure 1A). A similar increase
in anti-WTA IgG titer was observed in MBL KO mice after the
second immunization with WTA but not with PBS control
(Figure 1B). Anti-WTA IgG titers were incrementally increased in
both WT and MBL KO mice with serial immunizations.
(Figure 1A and 1B, respectively). No sign of rash or abscess
formation was observed at the injection sites throughout the study,
suggesting multiple WTA injections did not induce any local
adverse reaction. In addition, all mice gained weight by 3–8% and
appeared to be healthy and without signs of illness or unusual
behavior during and after the immunizations, suggesting that
WTA immunization did not have an adverse effect, physically or
mentally, in mice. These results demonstrate that naı¨ve mice,
raised in a pathogen free environment, do not have anti-WTA IgG
in serum and that intradermal WTA immunization both elicited
and augmented an anti-WTA IgG response, independent of the
presence of MBL.
Intradermal WTA immunization reduces susceptibility to
MRSA infection independent of MBL
We tested whether the enhanced anti-WTA IgG response from
intradermal WTA immunization confers protection from MRSA
infection. We used the abscess formation model following systemic
infection of sublethal inoculums of two MRSA strains, MW2 CA-
MRSA and COL HA-MRSA, as described above.
We first tested MW2 CA-MRSA infection. Abscess formation
was predominantly observed in the kidney of PBS control
immunized WT mice whereas no abscess formation was observed
in WTA-immunized WT mice (Figure 2A). In MBL KO mice,
intradermal WTA immunization had little effect in abscess
formation because no abscess formation was observed in both
PBS control immunized MBL KO mice (Figure 2A). Although
abscess formation was not observed in WTA-immunized WT and
MBL KO mice using MW2 CA-MRSA, culture of kidney
homogenates detected bacteria, suggesting that there was still
infection. Nevertheless, bacterial loads were significantly reduced
in WTA immunized WT mice while they were similar between
PBS control and WTA immunized MBL KO mice (Figure 2B).
Next, we tested COL HA-MRSA infection. Intradermal WTA
immunization reduced abscess formation in both MBL KO and
WT mice although statistical significance was obtained only for the
MBL KO mice group (Figure 3A). The bacterial loads of COL
HA-MRSA were significantly reduced in both MBL sufficient and
MBL deficient mice that were immunized with WTA (Figure 3B).
These results demonstrate that intradermal WTA immunization is
effective in reducing infection, as assessed by measurement of
abscess formation and bacterial loads, with both MW2 CA-MRSA
and COL HA-MRSA, independent of the presence of MBL.
Anti-WTA IgG containing serum activates complement
and inhibits MRSA growth in ex vivo whole blood assays
The complement activation activity of anti-WTA IgG in serum
was assayed by measuring C4c deposition, as described above.
Since C4C deposition is mediated by both the classical and the
Table 1. Abscess formation in systemic MRSA infection.
Bacterial strains COL HA-MRSA MW2 CA-MRSA
Mouse strains WT MBL WT MBL
Kidneys/Total (%) 8/18 (44) 10/18 (56) 10/24 (42) 0/24 (0)*
Mice/Total (%) 5/9 (55) 7/9 (78) 8/12 (66) 0/12 (0)*
*indicates p,0.0001 (Likelihood ratio) compared to WT in MW2 CA-MRSA
infection.
doi:10.1371/journal.pone.0069739.t001
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lectin pathways, the lectin pathway was minimized by using anti-
WTA IgG containing serum from MBL KO mice, in which the
lectin pathway activity is sharply curtailed due to the absence of
MBL. C4c deposition activity (mean OD reading 6 SD) was 0.
49960.056 and 0.38860.037 (p,0.002 by Student’s t test) for
WTA and PBS control immunized serum samples, respectively.
These results demonstrate that anti-WTA IgG containing serum is
able to initiate the classical complement pathway on the presence
of WTA.
Whole blood contains all of the soluble factors and a range of
effector cells for complement activation. Complement activation
and consequent inhibition of bacterial growth is a meaningful
assay of complement activity, including bactericidal activity, as we
have previously reported [12,21]. Therefore, we tested the ability
of anti-WTA serum to limit MRSA growth in ex vivo whole blood
assays. To analyze the effects of MBL in this setting, we examined
bacterial growth in a mixture of anti-WTA IgG containing serum
obtained from WTA-immunized MBL KO mice and whole blood
of naı¨ve WT and MBL KO mice.
Compared with PBS control immunized serum, anti-WTA IgG
containing serum significantly reduced bacterial growth of COL
HA-MRSA in whole blood of both WT and MBL KO mice
(Figure 4A and 4B, respectively). Similar bacterial growth
inhibition was obtained using MW2 CA-MRSA, with statistical
significance for MBL KO whole blood (Figure 4C and 4D).
Comparison of PBS control immunized serum from WT and
MBL KO mice showed significant reduction in COL HA-MRSA
growth by MBL KO serum while no significant difference was
observed for MW2 CA-MRSA (Figure 4). These results show that
anti-WTA IgG containing serum is able to inhibit MRSA growth
and reduce the numbers of MRSA in whole blood independent of
the presence of MBL.
Discussion
Our recent finding that healthy people have circulating anti-
WTA IgG led us to hypothesize that WTA immunization would
result in an anti-WTA response. We now report that this
hypothesis is correct, with the results provided here demonstrating
that intradermal WTA immunization elicits and augments anti-
WTA IgG production in mice, without use of an adjuvant. These
results provide in vivo evidence that WTA itself is immunogenic.
The incremental increase in IgG titer with serial WTA immuni-
zation suggests that WTA mediates a T cell-dependent antibody
response, which requires B cell germinal center formation [30].
Our unpublished observations show that intradermal WTA
immunization results in germinal centers (B220 and PNA double
positive splenocytes) adjacent to T cell zones in spleen. Taken
together, these observations suggest that WTA is a T cell-
dependent antigen, even though polysaccharide antigens have
previously been regarded as T cell-independent [31].
Figure 1. WTA immunization elicits and augments WTA-
specific IgG in WT (1A) and MBL KO mice (1B). PBS control or
5 mg of WTA was intradermally injected on days indicated by black
arrows. No adjuvant was used throughout the study. Four WT mice per
group and 5 MBL KO mice per group were used. Anti-WTA IgG serum
titers are plotted as mean ± SD. *, ** and *** indicates p,0.01, 0.001
and 0.0005 (Welch’s test).
doi:10.1371/journal.pone.0069739.g001
Figure 2. WTA immunization reduces MW2 CA-MRSA infection
in WT mice while no difference is seen in the absence of MBL.
(2A) Abscess formation. Mice immunized with PBS control or WTA were
infected 20 days after the last immunization. Abscess formation was
examined on day 10 following systemic infection with MW2 CA-MRSA
as detailed in the Materials and Methods. Abscess formation is
expressed as numbers of mice with abscess and total mice in each
group. * indicates p,0.0001 against all other groups (Likelihood Ratio).
(2B) Bacterial load in the kidney. Bacterial titers were measured in
homogenates of two combined kidneys and are expressed as cfu/g of
kidneys in a box plot. Numbers of mice used are as in figure 2A. * and
** indicates p,0.05 and p,0.001, respectively compared to WT
immunized with PBS control (Nonparametric comparisons for each pair
by Wilcoxon methods).
doi:10.1371/journal.pone.0069739.g002
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We note that we used highly purified WTA that does not
contain lipoproteins or LTA. The former was not present due to
an lgt gene mutation and the latter was efficiently removed during
our purification process [21,22]. Although we do not know
whether these molecules modulate anti-WTA antibody responses,
they do induce inflammation, whereas WTA does not [10,32,33].
Further investigation of the inflammatory response to WTA may
help to better understand the mechanisms of anti-WTA IgG
induction.
It has been reported that an abscess develops at the site of
subcutaneous injection when WTA and dextran are administered
together [10]. In contrast, we used an intradermal injection
without any adjuvant or other foreign material and did not
observe abscess formation even after multiple WTA injections. It is
well established that different host responses can be elicited from
the same antigen by manipulation of multiple factors, including
adjuvant or irritants such as dextran, and different routes of
injection, such as intradermal or subcutaneous [16,17,18,19].
Recent studies have demonstrated that intradermal administration
can produce a more effective immune response compared to other
routes of administration [34,35,36]. For example, intradermal
immunization resulted in protective immunity with tuberculosis
and hepatitis C virus vaccines, while subcutaneous injection failed
to elicit a response or was less effective [17].
In the results presented here we find that the anti-WTA IgG
response is not affected by the absence of MBL, the deficiency of
which is a common primary immunodeficiency in humans. In
contrast, in our prior study, MBL deficiency enhanced IgG
responses to certain antigens [27]. Of major significance for
purposes of clinical translation, the enhanced anti-WTA IgG
response confers protection from infection with both COL HA-
and MW2 CA-MRSA, regardless of MBL status. As both of these
strains were isolated from humans, we hypothesize that anti-WTA
IgG may contribute to protection from S. aureus infection in
humans. The results presented here demonstrate that intradermal
immunization with highly purified WTA effectively induces
adaptive immunity in mice, and we hypothesize that this will be
obtain in humans also.
An unexpected new finding in the current study is that MBL
deficiency relatively protects mice from infection with MW2 CA-
MRSA, as shown by decreased kidney abscess formation, while it
seems to have little effect on susceptibility to COL HA-MRSA
infection. MW2 is widely used as a strain of CA-MRSA (also
known as USA400), although S. aureus USA300 is now the most
commonly isolated CA-MRSA strain in the US. It is not known
whether MBL deficiency is protective from other strains of MRSA
bacteria. Nevertheless, these findings raise the possibility that some
strains of MRSA could utilize MBL, an opsonin, to evade the host
defense system. This possibility has been proposed as a mechanism
for some intracellular pathogens, such as tuberculosis and
leishmaniasis, although the precise molecular mechanisms are
not fully understood and further investigations are required
[37,38,39]. These findings may explain why MBL deficiency has
not been strongly associated with S. aureus infection in humans,
particularly in adults, and the exact role of MBL in relation to
MRSA associated virulence factors requires further investigation
[12,13,14].
We have chosen a model of abscess formation following
systemic inoculation to assess infection because abscess formation
requires bacterial tissue adhesion and invasion, which WTA has
been shown to promote [7,9,40,41]. Also, increased expression of
WTA and resultant thickening of the cell wall may contribute to
antibiotic resistance, in addition to an array of other virulence
factors, such as penicillin binding proteins and efflux pumps
[42,43,44,45,46]. In any case, the results from our investigations
suggest that targeting WTA is a promising approach to controlling
S. aureus infection.
The results presented here also suggest a mechanism of the
microbicidal action of anti-WTA IgG that limits bacterial growth
in whole blood. WTA has been implicated in facilitating bacterial
attachment to host cells and tissues. Data presented here, from
whole blood assays, suggest that anti-WTA IgG eliminates bacteria
in blood prior to the bacteria attaching to cells and invading
tissues. Our previous studies have also shown that human anti-
WTA IgG increases opsonophagocytosis, which is correlated with
increased bacterial killing [21,22]. These studies also have shown
that anti-WTA IgG, upon binding to S. aureus, activates the
classical complement pathway, and so anti-WTA IgG contributes
directly to bacterial killing by initiating membrane attack complex
formation. This current study also provides evidence that anti-
WTA IgG containing serum is able to activate the classical
pathway. Consequently, our data along with previously reported
results, suggest that anti-WTA IgG is involved with direct
bactericidal action and opsonophagocytic killing.
In summary, we present in vivo evidence that highly purified
WTA (with undetectable lipoproteins and peptidoglycans) is
immunogenic in a T cell-dependent manner, resulting in an
anti-WTA IgG response that is effective against MRSA infection.
The efficacy of anti-WTA immunity is not affected by MBL
sufficiency, although the role of MBL in MRSA infection is
variable, in that MBL deficiency is protective against MW2 CA-
MRSA infection while MBL inhibits COL HA-MRSA in whole
blood. These observations lead to the hypotheses that naturally
occurring anti-WTA adaptive immunity reduces susceptibility to
Figure 3. WTA immunization reduces COL HA-MRSA infection
in both MBL sufficient and MBL deficient mice. (3A) Abscess
formation. Mice immunized with PBS control or WTA were infected at
20 days after the last immunization. Abscess formation was examined
on day 10 following systemic infection with COL HA-MRSA as detailed
in the materials and methods. Abscess formation is expressed as
numbers of mice with abscess and total mice in each group. * indicates
p,0.001 against WTA immunized groups (Likelihood ratio test). (3B)
Bacterial load in the kidneys. Bacterial titers were measured in
homogenates of two combined kidneys and are expressed as cfu/g of
kidneys in a box plot. Numbers of mice used are as in figure 3A.
* indicates p,0.01 compared to WT immunized with PBS control
(Nonparametric comparisons for each pairs by Wilcoxon methods).
doi:10.1371/journal.pone.0069739.g003
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infection to S. aureus, particularly in the adult population, and that
high serum levels of MBL in humans may be a risk factor for
infection with some strains of S. aureus. However, as S. aureus
exposure in humans is multifactorial, involving skin and mucosa,
further investigation is warranted to understand the precise
mechanisms by which anti-WTA immunity is naturally mounted.
It is also possible that sub-components of WTA may modulate its
immunogenicity, and so studies of WTA variants may reveal more
precisely the mechanisms of anti-WTA immunity.
Lastly, it is also possible that a similar immunization protocol,
using purified WTA with an appropriate (or possibly no) adjuvant,
may maximize anti-WTA IgG response and provide protection
from S. aureus infection in humans. It may also be possible that
anti-WTA IgG could serve as a passive immunization therapy to
treat patients with established and difficult to treat S. aureus
infections.
Supporting Information
Figure S1 Supplemental figure 1. Kidneys with or without
abscess are shown.
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